Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $8.08 USD
Change Today -0.34 / -4.04%
Volume 1.1M
As of 2:55 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

830 Winter Street

Waltham, MA 02451

United States

Phone: 781-895-0600

Fax: 781-895-0611

ImmunoGen, Inc., a biotechnology company, develops targeted anticancer therapeutics. The company’s wholly owned clinical and preclinical product candidates are antibody-drug conjugates (ADCs), which use a monoclonal antibody to deliver a therapeutic agent to targeted cells. The company developed its ADC technology to enable the creation of well-tolerated anticancer products. An ADC with its technology comprises an antibody that binds primarily to an antigen target found on the surface of cancer cells with one of its potent cancer-cell killing agents, or payloads, attached to the antibody using one of its engineered linkers. An ADC compound's antibody component enables it to bind to cancer cells that have its antigen on their surface and the payload agent serves to kill these cancer cells. The company has tubulin-acting payload agents, such as DM1 and DM4, which are maytansinoids. The company developed DNA-acting payload agents, such as DGN462, which the company calls IGNs. Its linkers are engineered to keep its payload agents attached to the antibody while traveling through the bloodstream and then control its release and activation once inside a cancer cell. The antibody component of an ADC might serve as a targeting vehicle or it might also have anticancer activity, depending on the antigen target and the antibody selected. The company develops its own product candidates using its ADC technology. It has three wholly owned, clinical-stage anticancer compounds—IMGN853, IMGN289, and IMGN529—and have reported preclinical data for IMGN779, which it expects to be its next clinical-stage compound. IMGN779 is the first ADC with its IGN technology. The company licenses to other companies limited rights to use its ADC technology with their antibodies to create products. The advanced compound with its ADC technology is the Roche Group’s (Roche's) marketed product, Kadcyla (ado-trastuzumab emtansine). The company’s partners are Amgen Inc. (Amgen); Bayer HealthCare AG (a subgroup of Bayer AG) (Bayer); Biotest AG (Biotest); Eli Lilly and Company (Lilly); Novartis Institutes for BioMedical Research, Inc. (Novartis); Roche; and sanofi-aventis U.S. LLC (Sanofi). The company also has a research agreement with CytomX Therapeutics, Inc. (CytomX) that allows each company to develop probody-drug conjugates against a specified number of cancer targets using CytomX's Probody antibody masking technology with the company’s payload agents and engineered linkers. Pipeline: Wholly Owned and Partner Product Candidates IMGN853 The company created its IMGN853 product candidate as a treatment for ovarian cancer, endometrial cancer, and other cancers that highly express folate receptor a (FRa). This ADC comprises a FRa-binding antibody with its potent DM4 payload agent attached using one of its engineered linkers. IMGN853 is in Phase I clinical testing. In July 2014, the company was granted orphan drug status for ovarian cancer by the U.S. Food and Drug Administration (FDA). IMGN853 is beginning assessment primarily for the treatment of FRa-positive platinum-resistant ovarian cancer and relapsed endometrial cancer. IMGN289 The company’s EGFR-targeting ADC, IMGN289, is a new treatment for cancers that highly express EGFR. These include squamous cell carcinoma of the head and neck, and types of non-small cell lung cancer (NSCLC), including both squamous cell and non-squamous cell NSCLCs. IMGN289 comprises an EGFR-binding antibody with the company’s DM1 payload agent attached using one of its engineered linkers. IMGN289 advanced into clinical testing in 2013. It is in the dose-finding portion of a Phase I clinical trial. IMGN529 The company’s IMGN529 ADC is a new treatment for cancers that highly express CD37, such as non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia. IMGN529 comprises a CD37-targeting antibody with its DM1 payload agent attached using one of its engineered linkers. IMGN529 is in the dose-finding portion of a Phase I clinical trial assessing it in patients with NHL previously treated with other anticancer agents. IMGN779 Preclinical-stage IMGN779 is a new treatment for acute myeloid leukemia


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMGN:US $8.08 USD -0.34

IMGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ablynx NV €10.08 EUR -0.04
Abzena PLC 82.00 GBp 0.00
BioInvent International AB kr1.91 SEK -0.02
Kyowa Hakko Kirin Co Ltd ¥1,755 JPY -1.00
MorphoSys AG €64.23 EUR -3.28
View Industry Companies

Industry Analysis


Industry Average

Valuation IMGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.2x
Price/Book 12.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOGEN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at